Hunter C. Smith - 01 Feb 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Chief Financial Officer
Signature
/s/ Hunter C. Smith
Issuer symbol
RYTM
Transactions as of
01 Feb 2023
Net transactions value
$0
Form type
4
Filing time
03 Feb 2023, 15:09:31 UTC
Previous filing
29 Dec 2022
Next filing
14 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Award $0 +19,700 $0.000000 19,700 01 Feb 2023 Common Stock 19,700 Direct F1, F2
transaction RYTM Stock Option (Right to Buy) Award $0 +53,600 $0.000000 53,600 01 Feb 2023 Common Stock 53,600 $27.35 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.
F3 The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.